News | December 30, 2021
Biological E gets nod to study Corbevax as a booster dose
The Subject Expert Committee has recommended grant of permission to conduct Phase 3 trials under certain conditions
The Subject Expert Committee has recommended grant of permission to conduct Phase 3 trials under certain conditions
The Subject Expert Committee (SEC), on Covid-19 of the Central Drugs Standard Control Organisation (CDSCO) on Monday recommended granting permission to manufacture and market anti-Covid pill molnupiravir for restricted emergency use
All the recommendations have been sent to the Drugs Controller General of India (DCGI) for final approval.
_256_384.jpg)
The two doses of Covaxin are likely to be administered to children with a gap of 28 days
Ampion is directly administered by inhalation and it allows the drug to directly target and attenuate inflammation in the lungs
The trial will be conducted across eight sites in Maharashtra
The trial will be conducted across 10 sites in India
The company has to approach the DCGI for approval to commence the trials
CDSCO gives the green signal as HGCO19 was safe, tolerable and immunogenic in the participants of the study
The Phase III clinical trial for NONS is expected to be completed by Q4 2021.
Subscribe To Our Newsletter & Stay Updated
